Literature DB >> 26721643

Gabapentin: Abuse, Dependence, and Withdrawal.

Tracey L Mersfelder1, William H Nichols2.   

Abstract

OBJECTIVE: To identify case reports and studies regarding patients who abused, became dependent on, or experienced withdrawal from gabapentin. DATA SOURCES: A PubMed literature search (1993 to October 2015) was performed using the search terms gabapentin, withdrawal, dependence, and addiction. Additional references were identified from a review of literature citations. STUDY SELECTION: All English-language case reports and studies were evaluated. DATA SYNTHESIS: A total of 18 case reports or case series were identified regarding addiction to or withdrawal from gabapentin. All the cases of addiction were in patients who had a previous history of alcohol, cocaine, or opioid abuse. On average, the patients were taking more than 3000 mg/d (600-8000 mg/d). Two surveys reported that the misuse of gabapentin was 1.1% in the general population and 22% in drug abuse treatment centers. Withdrawal, when reported, occurred within 12 hours to 7 days of discontinuation of the medication.
CONCLUSION: There have been numerous documented cases of gabapentin abuse, dependence, and withdrawal. Even though gabapentin is sometimes considered as a treatment option for alcohol and substance abuse, it is important to monitor for drug-seeking behaviors. A history of alcohol or substance abuse appears to be an important part of a patient's medical history when evaluating their risk for addiction and dependence behaviors. Health care providers need to be aware of this risk in their patients and monitor their patients for signs of abuse and dependence along with withdrawal symptoms.
© The Author(s) 2015.

Entities:  

Keywords:  clinical pharmacy; drug abuse; pain management; psychiatry; substance abuse; withdrawal

Mesh:

Substances:

Year:  2015        PMID: 26721643     DOI: 10.1177/1060028015620800

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  28 in total

1.  Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.

Authors:  Daniel E Falk; Megan L Ryan; Joanne B Fertig; Eric G Devine; Ricardo Cruz; E Sherwood Brown; Heather Burns; Ihsan M Salloum; D Jeffrey Newport; John Mendelson; Gantt Galloway; Kyle Kampman; Catherine Brooks; Alan I Green; Mary F Brunette; Richard N Rosenthal; Kelly E Dunn; Eric C Strain; Lara Ray; Steven Shoptaw; Nassima Ait-Daoud Tiouririne; Erik W Gunderson; Janet Ransom; Charles Scott; Lorenzo Leggio; Steven Caras; Barbara J Mason; Raye Z Litten
Journal:  Alcohol Clin Exp Res       Date:  2018-12-09       Impact factor: 3.455

2.  Gabapentin Abuse in a Patient with Comorbid Mood and Substance Use Disorders.

Authors:  Oleg V Tcheremissine; Durga Prasad Bestha
Journal:  Innov Clin Neurosci       Date:  2016-08-01

Review 3.  Medication Overuse in Chronic Pain.

Authors:  Eric S Hsu
Journal:  Curr Pain Headache Rep       Date:  2017-01

4.  Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition.

Authors:  Rob Hill; William L Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2018-05-07       Impact factor: 8.739

5.  A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.

Authors:  Rachel Vickers Smith; Elaine M Boland; April M Young; Michelle R Lofwall; Alexa Quiroz; Michele Staton; Jennifer R Havens
Journal:  Psychol Addict Behav       Date:  2017-12-14

6.  Risk to heroin users of polydrug use of pregabalin or gabapentin.

Authors:  Abigail Lyndon; Suzanne Audrey; Claudia Wells; Erica S Burnell; Suzanne Ingle; Rob Hill; Matthew Hickman; Graeme Henderson
Journal:  Addiction       Date:  2017-05-15       Impact factor: 6.526

7.  Complex encephalopathy arising from the combination of opioids and gabapentin.

Authors:  Harpreet Singh; Richa Handa; Vivek Kak; Alicja Wasilewski
Journal:  BMJ Case Rep       Date:  2019-04-20

8.  An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user.

Authors:  Mance E Buttram; Steven P Kurtz; Theodore J Cicero; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2019-09-13       Impact factor: 4.492

9.  Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice.

Authors:  Mahindra Chincholkar
Journal:  Br J Pain       Date:  2020-03-13

10.  Use of gabapentinoid medications among US adults with cancer, 2005-2015.

Authors:  Alex J Fauer; Matthew A Davis; Sung Won Choi; Lauren P Wallner; Christopher R Friese
Journal:  Support Care Cancer       Date:  2019-10-25       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.